Review article · 2022 · Open access
Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis
Frontiers in Immunology, 13, 977265 · Published 29 September 2022 · DOI 10.3389/fimmu.2022.977265
In brief
“Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis” is a 2022 review article by Li Liu and 5 co-authors, published in Frontiers in Immunology. OpenAlex counts 55 citations as of 19 November 2026, which puts it in the top 2% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 55
- Most cited in
- 2025 (22)
- Field-weighted impact
- 1.44
- References
- 50
- Authors
- 6
Abstract
Background: We aim to evaluate the efficacy and tolerability of Janus kinase inhibitors (JAKi) as monotherapy and in combination with methotrexate (MTX) in active rheumatoid arthritis (RA). Methods: Medline, EMBASE, and Cochrane Library were systematically searched to identify relevant randomized controlled trials (RCTs). Pooled analysis was conducted using random-effects model, along with the risk difference (RD) and 95% confidence intervals (CIs). Results: Three RCTs, including 2,290 patients, were included. JAKi (tofacitinib, baricitinib, and filgotinib) plus MTX displayed a higher proportion of patients meeting the American College of Rheumatology (ACR) criteria than JAKi alone at week 52 (ACR20 RD 0.032; 95% CI -0.027 to 0.091; ACR50 RD 0.050; 95% CI 0.003 to 0.097; ACR70 RD 0.056; 95% CI 0.012 to 0.100). Similar results were observed for ACR20/50/70 at week 24. No significant difference was found between two regimens for the proportion of patients achieving Health Assessment Questionnaire disability index (HAQ-DI) improvement ≥ 0.22 at weeks 24 and 52. Regarding low disease activity and remission achievement, JAKi in combination with MTX, contributed higher response rates than JAKi alone at weeks 24 and 52. Compared with JAKi monotherapy, combination therapy had a higher risks of treatment-emergent adverse events (TEAEs) and adverse events (AEs) leading to study discontinuation. Conclusion: JAKi combined with MTX demonstrated superiority to JAKi monotherapy in terms of ACR responses, low disease activity and remission achievement. The two regimens presented comparable physical functioning measured by HAQ-DI improvement and similar tolerability, except for high risks of TEAEs and AEs leading to study discontinuation in combination therapy. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021288907.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Liu, L., Yan, Y., Shi, F., Lin, H., Gu, Z., & Li, J. (2022). Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. Frontiers in Immunology, 13, 977265. https://doi.org/10.3389/fimmu.2022.977265
MLA 9
Liu, Li, et al. “Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.” Frontiers in Immunology, vol. 13, 2022, p. 977265. https://doi.org/10.3389/fimmu.2022.977265.
Chicago
Liu, Li, Yi–Dan Yan, Fang‐Hong Shi, Hou‐Wen Lin, Zhi‐Chun Gu, and Jia Li. 2022. “Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.” Frontiers in Immunology 13: 977265. https://doi.org/10.3389/fimmu.2022.977265.
Harvard
Liu, L. et al. (2022) ‘Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis’, Frontiers in Immunology, 13, p. 977265. doi:10.3389/fimmu.2022.977265.
IEEE
L. Liu, Y. Yan, F. Shi, H. Lin, Z. Gu, and J. Li, “Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis,” Frontiers in Immunology, vol. 13, p. 977265, 2022, doi: 10.3389/fimmu.2022.977265.
BibTeX
@article{liu2022comparative,
title = {{Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis}},
author = {Liu, Li and Yan, Yi–Dan and Shi, Fang‐Hong and Lin, Hou‐Wen and Gu, Zhi‐Chun and Li, Jia},
journal = {Frontiers in Immunology},
year = {2022},
volume = {13},
pages = {977265},
doi = {10.3389/fimmu.2022.977265},
url = {https://doi.org/10.3389/fimmu.2022.977265}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 8 | |
| 2024 | 14 | |
| 2025 | 22 | |
| 2026 | 11 |
Its field-weighted citation impact is 1.44: it has been cited 1.44 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- methotrexate
- tofacitinib
- baricitinib
- filgotinib
- combination therapy
- monotherapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Liu, L., Yan, Y., Shi, F., Lin, H., Gu, Z., & Li, J. (2022). Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. Frontiers in Immunology, 13, 977265. https://doi.org/10.3389/fimmu.2022.977265
How many times has this paper been cited?
55 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Li Liu, Yi–Dan Yan, Fang‐Hong Shi, Hou‐Wen Lin, Zhi‐Chun Gu, Jia Li.
What is the DOI of this paper?
10.3389/fimmu.2022.977265, permanently at https://doi.org/10.3389/fimmu.2022.977265. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.